The J-curve in arterial hypertension: Fact or fallacy?

Cardiology (Switzerland)

Volumn 129, Issue 2, 2014, Pages 126-135

  Tsika, Evangelia P ^a   Poulimenos, Leonidas E ^a   Boudoulas, Konstantinos Dean ^b   Manolis, Athanasios J ^a  

^a Asklepeion Voula Hospital   (Greece)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Coronary perfusion pressure; Diastolic blood pressure; Hypertension; J curve; Systolic blood pressure

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); COMORBIDITY; CORONARY ARTERY BLOOD FLOW; DIABETES MELLITUS; DRUG EFFECT; HUMAN; HYPERTENSION; ISOLATED SYSTOLIC HYPERTENSION; J CURVE PHENOMENON; ARTERIAL PRESSURE; CHRONIC KIDNEY FAILURE; COMPLICATION; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; DRUG EFFECTS; HEART LEFT VENTRICLE HYPERTROPHY; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE;

ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; DIABETIC ANGIOPATHIES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; STROKE; VASCULAR STIFFNESS;

EID: 84908513141     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000362381     Document Type: Article

References (58)

1. Pickering G: High Blood Pressure, ed 2. London, Churchill, 1968.
2. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970; 213: 1143-1152.
3. Hypertension Detection and Follow-Up Program Cooperative Group: Five-year findings of the Hypertension, Detection and Follow- Up Program. III. Reduction in stroke incidence among persons with high blood pressure. JAMA 1982; 247: 633-638.
4. Stewart IM: Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979; 1: 861-865.
5. Cruickshank JM, Thorp JM, Zacharias FJ: Benefits and potential harm of lowering blood pressure. Lancet 1987; 1: 581-584.
6. Farnet L, Mulrow CD, Linn WD, Lucey CR, Tuley MR: The J-curve phenomenon and the treatment of hypertension: is there a point beyond which pressure reduction is dangerous? JAMA 1991; 265: 489-495.
7. Morita K, Mori H, Tsujioka K, Kimura A, Ogasawara Y, Goto M, Hiramatsu O, Kajiya F, Feigl EO: Alpha-adrenergic vasoconstriction reduces systolic retrograde coronary blood flow. Am J Physiol 1997; 273:H2746- H2755.
8. Marino PL: Oxygen and carbon dioxide transport; in The ICU Book, ed 3. Lippincott, Williams & Wilkins, 2013, chapt 2, pp 21-38.
9. Libby P, Bonow RO, Mann DL, Zipes DP: Coronary blood flow and myocardial ischemia; in Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, ed 8. New York, Elsevier, 2008, chapt 48, pp 1167-1178.
10. Boudoulas H: Coronary arteries; in Leier CV, Boudoulas H (eds): Cardiorenal Disorders and Diseases, ed 2. Mount Kisco, Futura Publishing, 1992, pp 31-47.
11. Boudoulas H, Rittgers SE, Lewis RP, Leier CV, Weissler AM: Changes in diastolic time with various pharmacologic agents: implication for myocardial perfusion. Circulation 1979; 60: 164-169.
12. Boudoulas H, Leier CV: Clinical perspectives: myocardial perfusion pressure in the age of afterload reduction. ACC Current Journal Review, Sept-Oct 2000, pp 27-31.
13. Harrison DG, Barnes DH, Hiratzka LF, Eastham CL, Kerber RE, Marcus ML: The effect of cardiac hypertrophy on the coronary collateral circulation. Circulation 1985; 71: 1135- 1145.
14. Harrison DG, Florentine MS, Brooks LA, Cooper SM, Marcus ML: The effect of hypertension and left ventricular hypertrophy on the lower range of coronary autoregulation. Circulation 1988; 77: 1108-1115.
15. Pepi M, Alimento M, Maltagliati A, Guazzi MD: Cardiac hypertrophy in hypertension. Repolarization abnormalities elicited by rapid lowering of pressure. Hypertension 1988; 11: 84-91.
16. Raphael CE, Whinnett ZI, Davies JE, Fontana M, Ferenczi EA, Manisty CH, Mayet J, Francis DP: Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart 2009; 95: 56-62.
17. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, Laurent S: Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: A longitudinal study. Hypertension 2002; 39: 10-15.
18. Williams B: The aorta and resistant hypertension. J Am Coll Cardiol 2009; 53: 452-454.
19. Franklin SS, Larson MG, Kgan SA, Wong ND, Leip EP, Kannel WB, Levy D: Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245-1249.
20. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
21. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A: Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst- Eur) Trial Investigators. Lancet 1997; 350: 757.
22. Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE: Elevated heart rate and atherosclerosis: An overview of the pathogenetic mechanisms. Int J Cardiol 2008; 126: 302-312.
23. Safar ME, Protogerou AD, Blacher J: Statins, central blood pressure, and blood pressure amplification. Circulation 2009; 119: 9-12.
24. Williams B, Lacy PS: CAFE and the ASCOT (Anglo-Scandinavian Outcomes Trial) Investigators: Impact of heart rate on central aortic pressures and hemodynamics: Analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE Heart Rate. J Am Coll Cardiol 2009; 54: 705-713.
25. Wiliams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2009; 119: 9-12.
26. Bangalore S, Sawhney S, Messerli FH: Relation of β-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008; 52: 1482-1489.
27. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507- 1513.
28. Gillmann MW, Kannel WB, Belanger A, D'Agostino RB: Influence of heart rate on mortality among persons with hypertension: The Framingham Study. Am Heart J 1993; 125: 1148-1154.
29. Palatini P, Benetos A, Grassi G, Julius S, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Pessina AC, Ruilope LM, Zanchetti A: Identification and management of the hypertensive patient with elevated heart rate: Statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006; 24: 603-610.
30. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
31. Poulter NR, Dobson JE, Sever PS, Dahlof B, Wedel H, Campbell NR; ASCOT Investigators: Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol 2009; 54: 1154-1161.
32. Pepine CJ, Handberg EM, Cooper-De Hoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW: A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003; 290: 2805-2816.
33. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ: Dogma disputed: can aggressively lowering blood pressure for hypertension in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884-893.
34. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Bohm M, Williams B, Pogue J, Koon T, Yusuf S: Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27: 1360-1369.
35. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagart R, Verdecchia P, Weber M, Bohm M, Williams B, Yusoff K, Teo K, Yusuf S: Safety and efficacy of low blood pressures among patients with diabetes: Subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol 2012; 59: 74-83.
36. Bangalore S, Messerli FH, Wun C-C, Zuckerman AL, DeMicco D, Kostis JB, LaRosa LC; Treating to New Targets Steering Committee and Investigators: J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) trial. Eur Heart J 2010; 31: 2897-2908.
37. Dorresteijn JA, van der Graaf Y, Spiering W, Grabbee DE, Bots ML, Visseren Fl: Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited. Hypertension 2012; 59: 14-21.
38. Hanson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S; for the HOT Study Group: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.
39. Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G: The Multiple Risk Factor Intervention Trial (MRFIT). A national study of primary prevention of coronary artery disease. JAMA 1976; 235: 825-827.
40. Glynn RJ, L'Italien GJ, Sesso HD, Jackson EA, Buring JE: Development of predictive models for long term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension 2002; 39: 105-110.
41. Boutitie F, Gueyffier F, Pocock S, Fagard R; Pierre Boissel for the INDANA Project Steering Committee: J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a metaanalysis of individual-patient data. Ann Intern Med 2002; 136: 438-448.
42. Turner R, Holman R, Stratton I, Cull C, Frighi V, Manley S, Matthews D, Neil A, McElroy H, Kohner E, Fox C, Hadden D, Wright D; UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
43. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-1097.
44. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F; The ACCORD Study Group: Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585.
45. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B; ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (The ADVANCE trial): A randomized controlled trial. Lancet 2007; 370: 829-840.
46. Vamos EP, Harris M, Millet C, Pape UJ, Khunti K, Curcin V, Molokhia M, Majeed A: Association of systolic and diastolic blood pressure and all-cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study. BMJ 2012; 345:e5567.
47. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219.
48. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
49. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033-1041.
50. Ovbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R, Donnan GA, Bath PM: Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 2011; 306: 2137-2144.
51. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL: Blood pressure control, proteinuria and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754- 762.
52. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and hypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.
53. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J: Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661.
54. Jafar TH, Stark PC, Scmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252.
55. Kovesdy CP, Bleyer AJ, Molnar MZ, Sim JJ, Cushman WC, Quarles LD, Zaden KK: Blood pressure and mortality in US Veterans with chronic kidney disease: A cohort study. Ann Intern Med 2013; 159: 302-303.
56. Cole A: Risk of death found to be raised in chronic kidney disease patients with low diastolic blood pressure. BMJ 2013; 347:f5201.
57. Wood PH: Diseases of the Heart and Circulation. London, Eyre & Spottiswoode, 1950.
58. Messerli FH, Mancia G, Conti CR, et al: Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884-893.